14-day Premium Trial Subscription Sign Up For FreeGet Free

Catalyst Biosciences Stock Forecast NASDAQ:CBIO

Price Target and Analyst Ratings

Most Recent Rating

On September 10, 2021 "Jonestrading" gave "$18.00" rating for CBIO. The price target was set to $4.65+0.0%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-10 $18.00 Reiterated by Jonestrading $4.65 $4.65+0.0%
2021-08-09 $18.00 Initiated by Jonestrading $4.26 $4.34→0.7%
2021-08-06 $19.00 - $18.00 Target Lowered by Raymond James $4.37 $4.30+5.1%
2021-07-20 $4.31 Target Set by Raymond James $4.51 $4.45+3.2%
2021-07-20 Reiterated by Raymond James $4.51 $4.31→1.4%
2021-07-01 Buy Reiterated by Chardan Capital $4.35
2021-05-05 Outperform Target Raised by Raymond James $4.64 $18.00 → $19.00
2021-04-29 Outperform Target Raised by Raymond James $5.20 $18.00 → $19.00
2021-03-04 Outperform Target Set by Raymond James $5.89 $18.00
2021-02-10 Overweight Initiated by Piper Sandler $6.92 $15.00
2021-02-04 Outperform Target Lowered by Raymond James $5.75 $20.00 → $18.00
2020-12-15 Outperform Target Set by Raymond James $7.23 $20.00
2020-12-03 Outperform Reiterated by Raymond James $5.71 $20.00
2020-12-03 Outperform Target Set by Raymond James $5.71 $20.00
2020-11-05 Outperform Reiterated by Lifesci Capital $5.81
2020-11-05 Buy Reiterated by Raymond James $5.81 $20.00
2020-08-07 Outperform Target Set by Raymond James $5.39 $20.00
2020-08-06 Buy Reiterated by Ci Capital $5.37 $18.00
2020-07-22 Buy Reiterated by Ci Capital $5.85 $19.00
2020-07-14 Outperform Target Set by Raymond James $5.59 $20.00
2020-06-17 Outperform Target Set by Raymond James $7.27 $20.00
2020-06-11 Outperform Target Set by Raymond James $7.18 $20.00
2020-05-21 Outperform Initiated by Raymond James $7.14 $20.00

CBIO Stock Trend

The stock has broken the very wide and weak rising the short-term trend up and an even stronger rate of rising is indicated. For any reaction back there will now be support on the roof on the current trend broken at $4.87, a level that may pose a second chance to hit a runner. According to fan-theory $5.87 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

Data

Date Bottom Mid Top
2021-09-20 $3.88 $4.37 $4.87
2021-09-21 $3.88 $4.38 $4.88
2021-09-22 $3.88 $4.38 $4.88
2021-09-23 $3.89 $4.39 $4.89
2021-09-24 $3.89 $4.39 $4.89
2021-09-27 $3.90 $4.40 $4.90
2021-09-28 $3.90 $4.40 $4.90
2021-09-29 $3.91 $4.41 $4.91
2021-09-30 $3.91 $4.41 $4.91
2021-10-01 $3.92 $4.42 $4.92
2021-10-04 $3.92 $4.42 $4.92
2021-10-05 $3.92 $4.42 $4.92
2021-10-06 $3.93 $4.43 $4.93
2021-10-07 $3.93 $4.43 $4.93
2021-10-08 $3.94 $4.44 $4.94
2021-10-11 $3.94 $4.44 $4.94
2021-10-12 $3.95 $4.45 $4.95
2021-10-13 $3.95 $4.45 $4.95
2021-10-14 $3.96 $4.46 $4.96
2021-10-15 $3.96 $4.46 $4.96
2021-10-18 $3.97 $4.47 $4.96
2021-10-19 $3.97 $4.47 $4.97
2021-10-20 $3.97 $4.47 $4.97
2021-10-21 $3.98 $4.48 $4.98
2021-10-22 $3.98 $4.48 $4.98
2021-10-25 $3.99 $4.49 $4.99
2021-10-26 $3.99 $4.49 $4.99
2021-10-27 $4.00 $4.50 $5.00
2021-10-28 $4.00 $4.50 $5.00
2021-10-29 $4.01 $4.51 $5.01

About Catalyst Biosciences

Catalyst Biosciences Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs. Its product pipeline includes CB 813d, a Factor VIIa drug candidate that completed a Phase I clinical trials evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT